GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

Status Recruiting

Clinical Trial Summary

The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN3014 dose to be tested in a larger group of participants and assess preliminary clinical activity of GEN3014. GEN3014 will be studied in relapsed or refractory multiple myeloma (also known as RRMM) and other blood cancers. The study consists of 3 parts: 1. The Dose Escalation will test increasing doses of GEN3014 to find a safe dose level to be tested in the other two parts. 2. Expansion Part A will further test the GEN3014 dose determined from the Dose Escalation Part. 3. Expansion Part B will compare intravenous (IV) GEN3014 with the subcutaneous (SC) daratumumab in ex-US countries. Participants will receive either GEN3014 or daratumumab; none will be given placebo. The study duration will be different for the individual participants. Overall, the study may be ongoing up to 5 years after the last participant's first treatment.

Clinical Trial Description

This trial will be conducted in 3 parts: Dose Escalation (phase 1), Expansion Parts, A and B (phase 2). In the dose escalation phase GEN314 will be evaluated in RRMM and relapsed and refractory acute myeloid leukemia (R/R AML). The participants will receive GEN3014 administered at various dose levels in 28 day cycles. Dose Limiting Toxicities (DLTs) will be assessed during the first treatment cycle and the Maximum Tolerated Dose (MTD) and/or Recommended phase 2 dose (RP2D) will be determined. In Expansion Part A, GEN3014 will be further evaluated in 4 cohorts: anti-CD38 monoclonal antibody (mAb)-naive RRMM, anti-CD38 mAb-refractory RRMM, relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), and R/R AML at the RP2D identified from the Dose Escalation per protocol. In Expansion Part B, GEN3014 IV will be compared to daratumumab SC, head-to-head (H2H) to evaluate whether GEN3014 may be more potent in anti-CD38 mAb-naïve RRMM participants. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04824794
Study type	Interventional
Source	Genmab
Contact	Genmab Trial Information
Phone	+45 70202728
Email	clinicaltrials@genmab.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	March 9, 2021
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04240002` - A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)	Phase 1/Phase 2
Completed	`NCT02626715` - Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS	Phase 2
Completed	`NCT05488613` - Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
Completed	`NCT02265731` - Study Evaluating Venetoclax in Subjects With Hematological Malignancies	Phase 1/Phase 2
Terminated	`NCT02927938` - Leukemia Stem Cell Detection in Acute Myeloid Leukemia	Phase 3
Completed	`NCT01772953` - Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT	Phase 2
Recruiting	`NCT03188874` - Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Completed	`NCT00071006` - AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)	Phase 2
Completed	`NCT04079296` - A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)	Phase 1/Phase 2
Completed	`NCT04509622` - A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)	Phase 3
Withdrawn	`NCT03699384` - Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)	Phase 1/Phase 2
Recruiting	`NCT03613532` - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	Phase 1
Completed	`NCT02252107` - 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1	Phase 2
Terminated	`NCT02259348` - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation	Phase 2
Terminated	`NCT01463410` - Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler	N/A
Completed	`NCT01242774` - Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)	Phase 1
Terminated	`NCT02134782` - Yoga Fatigue Study	N/A
Completed	`NCT01685619` - AML-MDS Novel Prognostic Tests Clinical Study
Completed	`NCT03625505` - A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia	Phase 1
Active, not recruiting	`NCT04266795` - A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy	Phase 2